Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Rabin

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Bone Marrow Transplantation|February 14, 2018
Use of split peripheral blood stem cell harvests in myeloma identifies functional preservation of progenitor cells cryopreserved for several years and demonstrates no functional damage to the bone marrow microenvironmentMichael John Watts, Stuart James Ings, Jude Dorman, et al.
British Journal of Haematology|April 11, 2016
Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapseYasmin Reyal, Rakesh Popat, Simon Cheesman, et al.
BMJ Open|February 1, 2020
PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myelomaOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2023
Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trialOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Frontiers in Oncology|March 13, 2023
Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providersGordon Cook, John Ashcroft, Mariana Fernandez, et al.
British Journal of Haematology|June 24, 2023
Functional and psychological impact of minimal residual disease assessment on patients with multiple myelomaNuno Correia, Emma Dowling, Rakesh Popat, et al.
British Journal of Haematology|August 9, 2014
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myelomaRakesh Popat, Iftekhar Khan, Jenny Dickson, et al.
British Journal of Haematology|January 16, 2016
Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM modelDeepika Kassen, Darren Lath, Anna Lach, et al.
BMJ Open|April 9, 2022
Adaptation of the PERCEPT myeloma prehabilitation trial to virtual delivery: changes in response to the COVID-19 pandemicOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
British Journal of Haematology|January 18, 2021
A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patientsSarah Bird, Charlotte Pawlyn, Susanna Nallamilli, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Bone Marrow Transplantation|February 14, 2018
Use of split peripheral blood stem cell harvests in myeloma identifies functional preservation of progenitor cells cryopreserved for several years and demonstrates no functional damage to the bone marrow microenvironmentMichael John Watts, Stuart James Ings, Jude Dorman, et al.
British Journal of Haematology|April 11, 2016
Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapseYasmin Reyal, Rakesh Popat, Simon Cheesman, et al.
BMJ Open|February 1, 2020
PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myelomaOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2023
Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trialOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
Frontiers in Oncology|March 13, 2023
Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providersGordon Cook, John Ashcroft, Mariana Fernandez, et al.
British Journal of Haematology|June 24, 2023
Functional and psychological impact of minimal residual disease assessment on patients with multiple myelomaNuno Correia, Emma Dowling, Rakesh Popat, et al.
British Journal of Haematology|August 9, 2014
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myelomaRakesh Popat, Iftekhar Khan, Jenny Dickson, et al.
British Journal of Haematology|January 16, 2016
Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM modelDeepika Kassen, Darren Lath, Anna Lach, et al.
BMJ Open|April 9, 2022
Adaptation of the PERCEPT myeloma prehabilitation trial to virtual delivery: changes in response to the COVID-19 pandemicOrla McCourt, Abigail Fisher, Gita Ramdharry, et al.
British Journal of Haematology|January 18, 2021
A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patientsSarah Bird, Charlotte Pawlyn, Susanna Nallamilli, et al.
Pageof 8